Vestal Point Capital, LP Portfolio Holdings

Vestal Point Capital, LP

  • $1.32 Trillion
  • Q3 2024

Vestal Point Capital, LP has filed its 13F form on November 14, 2024 for Q3 2024 where it was disclosed a total value porftolio of $1.32 Trillion distributed in 69 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Insmed Inc with a value of $117B, Jazz Pharmaceuticals PLC with a value of $100B, Cytokinetics Inc with a value of $79.2B, Inari Medical, Inc. with a value of $63.9B, and Arcellx, Inc. with a value of $56.4B.

Examining the 13F form we can see an decrease of $22.5B in the current position value, from $1.34T to 1.32T.

Vestal Point Capital, LP is based out at New York, NY

Below you can find more details about Vestal Point Capital, LP portfolio as well as his latest detailed transactions.

Portfolio value $1.32 Trillion
Healthcare: $1.09 Trillion

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$8.84B
$117 Billion 8.86% of portfolio
1,600,000
Q3 2024 Added 113.33%
$7.61B
$100 Billion 7.6% of portfolio
900,000
Q3 2024 Reduced 40.0%
$4.39B
$79.2 Billion 6.01% of portfolio
1,500,000
Q3 2024 Reduced 27.71%
$4.23B
$63.9 Billion 4.85% of portfolio
1,550,000
Q3 2024 Added 342.86%
$3.02B
$56.4 Billion 4.27% of portfolio
675,000
Q2 2024 Added 575.0%
Structure Therapeutics Inc
-
$50.5 Billion 3.83% of portfolio
-
Q3 2024 Added 105.36%
$193M
$46.3 Billion 3.51% of portfolio
4,000,000
Q3 2024 Added 73.91%
$118M
$44 Billion 3.34% of portfolio
4,000,000
Q3 2024 Added 23.08%
$490M
$42.8 Billion 3.24% of portfolio
3,750,000
Q3 2024 Added 36.36%
$2.95B
$41.7 Billion 3.16% of portfolio
750,000
Q3 2024 Reduced 58.33%
$7.21B
$37.3 Billion 2.83% of portfolio
250,000
Q3 2024 Reduced 66.67%
Soleno Therapeutics Inc
-
$36.4 Billion 2.76% of portfolio
-
Q3 2024 Reduced 40.0%
$867M
$34.8 Billion 2.64% of portfolio
2,500,000
Q3 2024 Added 100.0%
$317M
$34.3 Billion 2.6% of portfolio
8,090,000
Q3 2024 Added 24.65%
$1.89B
$33.8 Billion 2.56% of portfolio
760,000
Q3 2024 New
$2.39B
$32.5 Billion 2.46% of portfolio
825,000
Q3 2024 Added 57.14%
$647M
$23.4 Billion 1.78% of portfolio
4,750,000
Q2 2024 Added 0.53%
$1.95B
$22 Billion 1.67% of portfolio
485,000
Q3 2024 Reduced 33.1%
$70.1M
$21.9 Billion 1.66% of portfolio
5,028,500
Q3 2024 Added 139.45%
Solid Biosciences Inc
-
$19.5 Billion 1.48% of portfolio
-
Q3 2024 Added 5.07%
$45.4B
$18.1 Billion 1.38% of portfolio
275,000
Q3 2024 New
$113B
$16.8 Billion 1.27% of portfolio
200,000
Q3 2024 New
$785M
$15 Billion 1.14% of portfolio
1,500,000
Q3 2024 Reduced 18.03%
$40.7B
$14.8 Billion 1.13% of portfolio
100,000
Q3 2024 New
$119B
$12.9 Billion 0.98% of portfolio
250,000
Q3 2024 Reduced 50.0%
Gsk PLC
-
$12.3 Billion 0.93% of portfolio
-
Q3 2024 New
Bicara Therapeutics Inc
-
$10.8 Billion 0.82% of portfolio
-
Q3 2024 New
Dianthus Therapeutics Inc
-
$10.8 Billion 0.82% of portfolio
-
Q3 2024 Reduced 34.17%
$276M
$10.5 Billion 0.79% of portfolio
1,025,000
Q3 2024 Reduced 41.43%
$2.18B
$10.5 Billion 0.79% of portfolio
205,000
Q3 2024 New
$32.7M
$9.73 Billion 0.74% of portfolio
1,145,000
Q3 2024 Reduced 78.91%
$860M
$9.55 Billion 0.72% of portfolio
425,000
Q3 2024 Reduced 15.0%
$122B
$8.64 Billion 0.66% of portfolio
150,000
Q3 2024 New
$9B
$8.63 Billion 0.65% of portfolio
125,000
Q3 2024 New
Apogee Therapeutics Inc
-
$8.02 Billion 0.61% of portfolio
-
Q3 2024 New
Zymeworks Inc
-
$7.72 Billion 0.59% of portfolio
-
Q3 2024 Added 39.77%
Lexeo Therapeutics Inc
-
$7.68 Billion 0.58% of portfolio
-
Q3 2024 Added 1.19%
$1.4B
$7.56 Billion 0.57% of portfolio
230,000
Q3 2024 New
Alto Neuroscience Inc
-
$7.44 Billion 0.56% of portfolio
-
Q3 2024 Added 4.84%
$66.6B
$7.23 Billion 0.55% of portfolio
30,000
Q3 2024 New
$5.8B
$6.37 Billion 0.48% of portfolio
30,000
Q3 2024 New
$5.63B
$6.09 Billion 0.46% of portfolio
125,000
Q3 2024 New
$143M
$5.9 Billion 0.45% of portfolio
1,685,000
Q3 2024 Reduced 15.75%
$233M
$5.08 Billion 0.39% of portfolio
400,000
Q3 2024 New
$1.69B
$5.18 Billion 0.39% of portfolio
180,000
Q2 2024 Added 38.46%
$266M
$4.93 Billion 0.37% of portfolio
930,000
Q3 2024 Added 4.49%
$1.2B
$4.77 Billion 0.36% of portfolio
1,050,000
Q3 2024 New
$36.5M
$4.27 Billion 0.32% of portfolio
6,100,000
Q3 2024 Added 0.79%
$296M
$4.2 Billion 0.32% of portfolio
1,500,000
Q3 2024 Reduced 31.82%

Summary

  • Portfolio
  • No. of Stocks 69
  • Current Value $1.32 Trillion
  • Prior Value $1.34 Trillion
  • Filing
  • Period Q3 2024
  • Filing Date November 14, 2024
  • Form Type 13F-HR
  • Activity in Q3 2024
  • New Purchases 23 stocks
  • Additional Purchases 22 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 17 stocks
Track This Portfolio

Track Vestal Point Capital, LP Portfolio

Follow Vestal Point Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vestal Point Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Vestal Point Capital, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email